Business Wire

CA-ENERGOUS

26.2.2020 22:04:06 CET | Business Wire | Press release

Share
Energous Secures Industry-first Regulatory Approval for its Revolutionary WattUp Wireless Charging Technology in Japan

Today Energous Corporation (Nasdaq: WATT), the developer of WattUp®, a revolutionary wireless charging 2.0 technology, announced that it has received regulatory approval for its WattUp Near Field wireless charging technology in Japan.

“Having secured regulatory approval for our WattUp wireless charging technology in Japan is a major regulatory milestone for Energous,” said Stephen R. Rizzone, president and CEO of Energous Corporation. “This opens the door to sell WattUp-enabled products in a major Asia Pacific market.”

Energous’ WattUp wireless charging technology underwent testing by independent, accredited test labs and was determined to be compliant with all regulatory requirements in Japan.

“WattUp approval in Japan is a big step forward for Energous and our customers, while increasing momentum to achieve global market access,” said Dan Lawless, vice president of regulatory affairs at Energous Corporation. “We are establishing a regulatory framework for the large-scale deployment of wireless charging 2.0 through our substantial engagements in major international spectrum and standards organizations, combined with our direct work with governments around the world.”

“Currently wireless charging technologies – specifically non coil-based charging solutions – have not yet penetrated the Japan market, largely because Japan has historically proven to have a more rigid regulatory approval process. Energous Corporation is paving the way for the industry in the Japan market with the industry-first approval of its WattUp wireless charging technology. With this breakthrough, Energous continues to show progress in advancing its WattUp technology to meet the needs of partner and customer companies,” said Dinesh Kithany, lead industry analyst, wireless power and power supply at Omdia.

Some of the benefits of Energous’ WattUp technology for manufacturers include:

  • A small footprint allowing WattUp to be integrated into products of various form factors, including small devices with curved edges or without flat surfaces
  • Orientation freedom and 90-degree angle support
  • Foreign object detection eliminating thermal issues with metal and other materials
  • Interoperability with all WattUp-enabled products, even those from different manufacturers

To-date, Energous has secured regulatory approval for its WattUp wireless charging technology in the following countries:

Afghanistan

Bermuda

Curacao

Germany

Kosovo

Netherlands

Suriname

Albania

Bolivia

Cyprus

Ghana

Latvia

New Zealand

Sweden

Andorra

Bosnia and Herzegovina

Czech Republic

Greece

Liechtenstein

Nicaragua

Switzerland

Angola

Botswana

Denmark

Grenada

Lithuania

Norway

Taiwan

Antigua and Barbuda

Brazil

Djibouti

Guatemala

Luxembourg

Panama

Tajikistan

Argentina

Brunei

Dominican Republic

Guyana

Macedonia

Peru

Tanzania

Armenia

Bulgaria

Dominica

Honduras

Malawi

Philippines

Thailand

Aruba

Burkina Faso

Ecuador

Hungary

Maldives

Poland

Trinidad and Tobago

Australia

Cambodia

Egypt

Iceland

Malta

Portugal

Turkey

Austria

Canada

El Salvador

India

Mexico

Romania

United Arab Emirates

Azerbaijan

Cayman Island

Eritrea

Indonesia

Monaco

Serbia

Uganda

Bahamas

Central African Republic

Estonia

Ireland

Mongolia

Slovenia

The United Kingdom

Barbados

Chile

Ethiopia

Italy

Montenegro

Solomon Island

The United States

Belarus

Colombia

Finland

Jamaica

Mozambique

Slovakia

Uruguay

Belgium

Costa Rica

France

Japan

Myanmar (formerly Burma)

South Africa

Uzbekistan

Belize

Croatia

Georgia

Jordan

Nepal

Spain

Venezuela

Energous anticipates it will receive regulatory approval in additional markets later this year.

To learn more about Energous, please visit Energous.com or follow the company on Twitter , Facebook and LinkedIn .

About Energous Corporation

Energous Corporation (Nasdaq: WATT) is leading the next generation of wireless charging – wireless charging 2.0 – with its award-winning WattUp® technology, which supports fast, efficient contact-based charging, as well as charging at a distance. WattUp is a scalable, RF-based wireless charging technology that offers substantial improvements in contact-based charging efficiency, foreign object detection, orientation freedom and thermal performance compared to older, coil-based charging technologies. The technology can be designed into many different sized electronic devices for the home and office, as well as the medical, industrial, retail and automotive industries, and it ensures interoperability across products. Energous develops silicon-based wireless power transfer (WPT) technologies and customizable reference designs. These include innovative silicon chips, antennas and software, for a large variety of applications, such as smartphones, fitness trackers, hearables, medical sensors and more. Energous received the world’s first FCC Part 18 certification for at-a-distance wireless charging, and the company has 220 awarded patents for its WattUp wireless charging technology to-date. For more information, please visit Energous.com .

Safe Harbor Statement

This press release contains forward-looking statements that describe our future plans and expectations. These statements generally use terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or similar terms. Examples of our forward-looking statements in this release include our statements about technology developments, partner product development and wireless charging innovation. Our forward-looking statements speak only as of this date; they are based on current expectations and we undertake no duty to update them. Factors that could cause actual results to differ from what we expect include: uncertain timing of necessary regulatory approvals; timing of customer product development and market success of customer products; our dependence on distribution partners; and intense industry competition. We urge you to consider those factors, and the other risks and uncertainties described in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, in evaluating our forward-looking statements.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye